| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.019 | 0.9 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.9 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |